Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today provides a business update highlighting the ...

Valtoco (diazepam nasal spray) is a prescription medicine for quick and effective treatment of seizure clusters, also known as acute repetitive seizures, in people with epilepsy. Seizure clusters are ...

Valtoco (diazepam) is a prescription drug that’s used to treat seizure clusters in adults and certain children. Valtoco comes as a nasal spray. Valtoco contains the active ingredient diazepam. It ...

Presentation highlights study-enrollment challenges and strategies to overcome potential barriers "Data from clinical studies of repetitive seizures in early childhood are critical to help advance new ...

SAN DIEGO, April 16, 2025 /PRNewswire/ -- Neurelis, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO® (diazepam nasal spray) for short-term treatment of ...

In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years. The Food and Drug ...

SAN DIEGO, Aug. 31, 2023 /PRNewswire/ -- Neurelis, Inc. will present additional clinical findings from the completed long-term, open-label, repeat-dose safety study of VALTOCO for the treatment of ...

Over 12,000 patients, age 2 to 5, prescribed VALTOCO following approval from the U.S. Food and Drug Administration (FDA) for an expanded indication. VALTOCO is now approved for children and adults ...

SAN DIEGO, Nov. 11, 2024 /PRNewswire/ -- Neurelis, Inc., today announced a presentation on insights into study design from the enrollment process for the new Stellina study investigating VALTOCO® ...

Neurelis announced the availability of Valtoco® (diazepam nasal spray) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute ...

VALTOCO maintains orphan drug exclusivity for VALTOCO to treat episodes of frequent seizures SAN DIEGO, April 16, 2025 /PRNewswire/ -- Neurelis, Inc., today announced that the U.S. Food and Drug ...